Japan to Assemble AIM-120 AMRAAMs; U.S. Targets 1,900+ Annual Production Under $20.7B Raytheon Contract
The announcement occurs in a context where Ukraine has consumed AMRAAM stocks faster than U.S. production can replenish them, and the Pentagon's Iran war cost estimate has risen 25% since July—much of that driven by air-defense munitions. Japan's facility is a co-production play, not a surge.
If Tokyo's share is 200-300 units annually (a reasonable estimate given the 1,900 target and the need to supply U.S. domestic consumption, Ukraine, and allied air forces), then Raytheon's U.S. lines still carry 1,600+ units per year, which requires the supplier base to expand in parallel. The deal signals political alignment on Indo-Pacific deterrence but exposes the hard truth: assembly is not the binding constraint—component fabrication is.
Raytheon's $20.7B AMRAAM contract was already stretched thin against current demand across the U.S., Japan, and Ukraine; the Japanese facility is a production-node addition, not a capacity escape hatch.
The real constraint is not assembly labor but component supply—circuit card assemblies, seekers, and rocket motors—which remain bottlenecked at U.S. suppliers. Tokyo's facility solves logistics and political optics (burden-sharing language for the Hill) but does not unlock the 1,900-unit annual target unless Raytheon simultaneously expands its upstream suppliers, which the $20.7B contract does not explicitly fund. Watch whether the FY27 supplemental includes separate appropriations for supplier capacity expansion—if not, the Japanese facility becomes a final-assembly theater with inventory backing up at the component tier.
What is the actual production capacity of the Japanese facility relative to the 1,900-unit annual target, and which U.S. suppliers are designated to feed it with components? The article does not disclose either.
Fault Lines
Strategic intelligence, synthesized daily — with a public track record. Every call graded against what actually happened.